Kevin S Cahill1, Elizabeth B Claus. 1. Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
OBJECT: The authors conducted a study to determine population-based estimates of survival following the diagnosis and treatment of nonmalignant intracranial meningioma in the US in the modern era. METHODS: Patients with nonmalignant intracranial meningioma were identified through the Surveillance, Epidemiology, and End Results (SEER) database for the years 2004-2007. Predictors of undergoing resection were identified and odds ratios calculated. Estimates of survival were calculated using Kaplan-Meier estimation method and Cox proportional hazards model. RESULTS: There were 12,284 patients with a diagnosis of nonmalignant intracranial meningioma included in the analysis. Only 55% had histological confirmation of the diagnosis of nonmalignant meningioma. Resection was used as an initial treatment in 43% of cases. Patients treated with surgery were more likely to be younger (OR 9.3, 95% CI 8.1-10.7, for resection in patients age 40-59 years compared with age > 80 years), male (OR 1.4, 95% CI 1.3-1.5, for males compared with females), white (OR 0.8, 95% CI 0.7-0.9, for black patients compared with white patients), and have larger tumors (OR 11.8, 95% CI 10.3-13.6, for tumors of the largest quartile compared with the smallest quartile). Patients treated with resection had a 3-year postdiagnosis survival estimate of 93.4% (95% CI 92.5%-94.3%) compared with 88.3% (95% CI 85.5%-90.6%) in patients not treated with resection (p < 0.01). Younger patient age, female sex, unilateral tumors, and resection were predictors of improved postdiagnosis survival after multivariate adjustment in patients with histologically confirmed meningiomas. conclusions: This analysis represents the first modern population-based analysis of treatment patterns and outcomes in US patients with nonmalignant intracranial meningioma. Over 85% of patients survive 3 years after diagnosis, and resection is associated with improved survival.
OBJECT: The authors conducted a study to determine population-based estimates of survival following the diagnosis and treatment of nonmalignant intracranial meningioma in the US in the modern era. METHODS:Patients with nonmalignant intracranial meningioma were identified through the Surveillance, Epidemiology, and End Results (SEER) database for the years 2004-2007. Predictors of undergoing resection were identified and odds ratios calculated. Estimates of survival were calculated using Kaplan-Meier estimation method and Cox proportional hazards model. RESULTS: There were 12,284 patients with a diagnosis of nonmalignant intracranial meningioma included in the analysis. Only 55% had histological confirmation of the diagnosis of nonmalignant meningioma. Resection was used as an initial treatment in 43% of cases. Patients treated with surgery were more likely to be younger (OR 9.3, 95% CI 8.1-10.7, for resection in patients age 40-59 years compared with age > 80 years), male (OR 1.4, 95% CI 1.3-1.5, for males compared with females), white (OR 0.8, 95% CI 0.7-0.9, for black patients compared with white patients), and have larger tumors (OR 11.8, 95% CI 10.3-13.6, for tumors of the largest quartile compared with the smallest quartile). Patients treated with resection had a 3-year postdiagnosis survival estimate of 93.4% (95% CI 92.5%-94.3%) compared with 88.3% (95% CI 85.5%-90.6%) in patients not treated with resection (p < 0.01). Younger patient age, female sex, unilateral tumors, and resection were predictors of improved postdiagnosis survival after multivariate adjustment in patients with histologically confirmed meningiomas. conclusions: This analysis represents the first modern population-based analysis of treatment patterns and outcomes in US patients with nonmalignant intracranial meningioma. Over 85% of patients survive 3 years after diagnosis, and resection is associated with improved survival.
Authors: K S Condra; J M Buatti; W M Mendenhall; W A Friedman; R B Marcus; A L Rhoton Journal: Int J Radiat Oncol Biol Phys Date: 1997-09-01 Impact factor: 7.038
Authors: B J McCarthy; F G Davis; S Freels; T S Surawicz; D M Damek; J Grutsch; H R Menck; E R Laws Journal: J Neurosurg Date: 1998-05 Impact factor: 5.115
Authors: Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers Journal: Neuro Oncol Date: 2012-03-09 Impact factor: 12.300
Authors: Therese A Dolecek; Emily Van Meter Dressler; Jigisha P Thakkar; Meng Liu; Abeer Al-Qaisi; John L Villano Journal: Cancer Date: 2015-04-14 Impact factor: 6.860
Authors: Joshua W Osbun; Philip D Tatman; Sumanpreet Kaur; Carolina Parada; Tina Busald; Luis Gonzalez-Cuyar; Min Shi; Donald E Born; Jing Zhang; Manuel Ferreira Journal: J Neurol Surg B Skull Base Date: 2017-04-26
Authors: Roy W R Dudley; Michelle R Torok; Sarah Randall; Benjamin Béland; Michael H Handler; Jean M Mulcahy-Levy; Arthur K Liu; Todd C Hankinson Journal: J Neurooncol Date: 2018-03-09 Impact factor: 4.130
Authors: Roy W R Dudley; Michelle R Torok; Danielle Gallegos; Arthur K Liu; Michael H Handler; Todd C Hankinson Journal: J Neurooncol Date: 2014-10-09 Impact factor: 4.130
Authors: Todd C Hankinson; Emma C Fields; Michelle R Torok; Brenda L Beaty; Michael H Handler; Nicholas K Foreman; Brent R O'neill; Arthur K Liu Journal: J Neurooncol Date: 2012-08-23 Impact factor: 4.130